IBSRELA Video Library

Select from the following topics

Video Vignettes


Short vignettes covering various topics related to IBSRELA and IBS-C

The importance of shared decision making

A patient and provider* describe the importance of shared decision-making with IBSRELA

*Susan is a compensated advisor to Ardelyx.
Individual results and experiences may vary.

Dr. Brian Lacy reviews important clinical data for IBSRELA from T3MPO-2

Dr. Brian Lacy reviews key clinical data for IBSRELA from T3MPO-2

Dr. Darren Brenner discusses treatment satisfaction with IBSRELA and quality-of-life improvement

Dr. Darren Brenner discusses IBSRELA patient-reported outcomes from T3MPO-2

Dr. Jignesh Shah shares his clinical experience with IBSRELA and discusses how he identifies patients that may benefit from a therapy with a different mechanism of action

Dr. Jignesh Shah’s clinical experience with IBSRELA

National Broadcasts


Hear from experts about IBS-C, the MOA of IBSRELA, and clinical data

Dr. Satish Rao presents: IBSRELA, an innovative treatment for IBS-C

Dr. Satish Rao presents: IBSRELA, a different mechanism of action for adults with IBS-C

Dr. Brooks Cash presents: IBSRELA, an innovative treatment for IBS-C in adults

Dr. Brooks Cash presents: IBSRELA, a different mechanism of action for adults with IBS-C

Case Studies


Dr. Satish Rao presents an IBSRELA patient case

Dr. Satish Rao presents an IBSRELA patient case

Leading gastroenterologists answer questions about IBSRELA


When can patients on IBSRELA expect to see results?
Answered by Dr. Darren Brenner

Are the results seen with IBSRELA durable?
Answered by Dr. Brian Lacy

Is IBSRELA a secretagogue?
Answered by Dr. Darren Brenner

Does IBSRELA exert an effect on NHE3 outside the GI tract?
Answered by Dr. Brian Lacy

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS

IBSRELA is contraindicated in patients less than 6 years of age; in nonclinical studies in young juvenile rats administration of tenapanor caused deaths presumed to be due to dehydration. Avoid use of IBSRELA in patients 6 years to less than 12 years of age. The safety and effectiveness of IBSRELA have not been established in patients less than 18 years of age.

CONTRAINDICATIONS

  • IBSRELA is contraindicated in patients less than 6 years of age due to the risk of serious dehydration.
  • IBSRELA is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.

WARNINGS AND PRECAUTIONS

Risk of Serious Dehydration in Pediatric Patients

  • IBSRELA is contraindicated in patients below 6 years of age. The safety and effectiveness of IBSRELA in patients less than 18 years of age have not been established. In young juvenile rats (less than 1 week old; approximate human age equivalent of less than 2 years of age), decreased body weight and deaths occurred, presumed to be due to dehydration, following oral administration of tenapanor. There are no data available in older juvenile rats (human age equivalent 2 years to less than 12 years).
  • Avoid the use of IBSRELA in patients 6 years to less than 12 years of age. Although there are no data in older juvenile rats, given the deaths in younger rats and the lack of clinical safety and efficacy data in pediatric patients, avoid the use of IBSRELA in patients 6 years to less than 12 years of age.

Diarrhea

Diarrhea was the most common adverse reaction in two randomized, double-blind, placebo-controlled trials of IBS-C. Severe diarrhea was reported in 2.5% of IBSRELA-treated patients. If severe diarrhea occurs, suspend dosing and rehydrate patient.

MOST COMMON ADVERSE REACTIONS

The most common adverse reactions in IBSRELA-treated patients (incidence ≥2% and greater than placebo) were: diarrhea (16% vs 4% placebo), abdominal distension (3% vs <1%), flatulence (3% vs 1%) and dizziness (2% vs <1%).

INDICATION

IBSRELA (tenapanor) is indicated for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults.

Please see full Prescribing Information, including Boxed Warning, for additional risk information.